Media stories about Vital Therapies (NASDAQ:VTL) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Vital Therapies earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.5026130025802 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of VTL traded down $0.50 during midday trading on Friday, reaching $5.95. 245,923 shares of the stock were exchanged, compared to its average volume of 185,556. Vital Therapies has a twelve month low of $2.25 and a twelve month high of $7.30. The stock has a market capitalization of $252.10, a P/E ratio of -4.54 and a beta of 4.26.
Vital Therapies (NASDAQ:VTL) last posted its earnings results on Tuesday, March 13th. The company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.04). During the same period last year, the business posted ($0.37) earnings per share. equities research analysts forecast that Vital Therapies will post -1.35 earnings per share for the current fiscal year.
About Vital Therapies
Vital Therapies, Inc, a biotherapeutic company, focuses on developing a human hepatic cell-based therapy targeting the treatment of acute forms of liver failure in the United States. Its ELAD system is an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials to allow the patient's own liver to potentially regenerate to a healthy state or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.